Link Pharma Chem

Why is Link Pharma Chem Ltd falling/rising?

As of 01-Sep, Link Pharma Chem Ltd's stock price is rising to Rs 28.20, marking a 4.14% increase after a trend reversal following five days of decline. Despite a year-to-date drop of 8.44%, the stock's recent performance and relative outperformance in the sector suggest a potential recovery, although trading volume has decreased significantly.

As of 01-Sep, Link Pharma Chem Ltd's stock price is rising, currently at Rs 28.20, reflecting an increase of Rs 1.12 or 4.14%. This upward movement is notable as it comes after a trend reversal, with the stock gaining after five consecutive days of decline. Additionally, the stock opened with a significant gain of 4.99% today and reached an intraday high of Rs 28.43.<BR><BR>The stock has outperformed the sector by 4.56%, indicating a positive performance relative to its peers. Despite a year-to-date decline of 8.44% and a one-year drop of 18.19%, the recent performance suggests a potential recovery phase. However, it is important to note that the stock's trading volume has shown erratic patterns, with a significant drop in delivery volume by 56.35% against the five-day average, which could indicate falling investor participation.<BR><BR>Overall, the combination of today's positive price movement, the trend reversal after previous declines, and the stock's relative outperformance in the sector contribute to the current rise in Link Pharma Chem Ltd's stock price.

Who are in the management team of Link Pharma Chem?

The management team of Link Pharma Chem consists of S G Thakur (Chairman & Wholetime Director), Rishikesh S. Thakur (Managing Director), and independent directors S B Dhatrak, Devang U Shah, and Rachna Ghai.

The management team of Link Pharma Chem includes the following individuals:<BR><BR>1. S G Thakur - Chairman & Wholetime Director<BR>2. Rishikesh S. Thakur - Managing Director<BR>3. S B Dhatrak - Independent Director<BR>4. Devang U Shah - Independent Director<BR>5. Rachna Ghai - Independent Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Link Pharma Chem do?

Link Pharma Chem Ltd is a mid-sized chemical manufacturing company specializing in Commodity Chemicals, with a production capacity that has expanded significantly since its incorporation in 1986. As of June 2026, it reported net sales of 9 Cr and a market cap of INR 12 Cr.

Overview:<BR>Link Pharma Chem Ltd is a mid-size leading chemical manufacturing company in the Commodity Chemicals industry, operating within the Micro Cap market-cap bracket.<BR><BR>History:<BR>Incorporated in 1986, Link Pharma Chem has undergone several capacity expansions, increasing its production from 300 tpa of thionil chloride to 2100 tpa by 1994. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 9 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap: INR 12 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 502,820,444,094,278,528.00 <BR>Industry P/E: 43 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.52 <BR>Return on Equity: 0.00% <BR>Price to Book: 0.97 <BR><BR>Contact Details:<BR>Address: 162, GIDC Ind Estate Nandesari Vadodara Gujarat : 391340 <BR>Tel: 91-0265-3065000/2840448/3093931 <BR>Email: linkpharmacs@gmail.com <BR>Website: http://www.linkpharmachem.co.in

Who are the peers of the Link Pharma Chem?

Link Pharma Chem's peers include Vivid Global, Jayshree Chem., Square Four Pro., Tulasee Bio-Eth., Kobo Biotech, Emmessar Biotech, Omkar Pharmachem, Sreechem Resins, and Kuwer Industries. Link Pharma Chem has a 1-year return of -18.31%, better than Jayshree Chem.'s -26.68% but worse than Kobo Biotech's 134.04%.

Peers: The peers of Link Pharma Chem are Vivid Global, Jayshree Chem., Square Four Pro., Tulasee Bio-Eth., Kobo Biotech, Emmessar Biotech, Omkar Pharmachem, Sreechem Resins, and Kuwer Industries.<BR><BR>Quality Snapshot: Below Average management risk is observed at Vivid Global, Jayshree Chem., Emmessar Biotech, Link Pharma Chem, Kuwer Industries, and the rest. Good capital structure is found at Vivid Global, while Below Average capital structure is noted at Jayshree Chem., Emmessar Biotech, Link Pharma Chem, Sreechem Resins, Kuwer Industries, and the rest. Growth ratings are Below Average for Vivid Global, Link Pharma Chem, Emmessar Biotech, and Kuwer Industries, while Average growth is seen at Jayshree Chem. Square Four Pro., Tulasee Bio-Eth., Kobo Biotech, and Omkar Pharmachem do not qualify for any ratings.<BR><BR>Return Snapshot: Kobo Biotech has the highest 1-year return at 134.04%, while Jayshree Chem. has the lowest at -26.68%. Link Pharma Chem's 1-year return is -18.31%, which is better than Jayshree Chem. but worse than Kobo Biotech. Additionally, the six-month returns for Omkar Pharmachem and Sreechem Resins are negative.

How big is Link Pharma Chem?

As of 31st August, Link Pharma Chem Ltd has a market capitalization of 12.00 Cr and reported net sales of 28.38 Cr with no net profit in the latest four quarters. Shareholder's funds were 12.79 Cr and total assets were 24.81 Cr as of March 2026.

As of 31st August, Link Pharma Chem Ltd has a market capitalization of 12.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Link Pharma Chem reported net sales of 28.38 Cr. The net profit for the same period was 0.00 Cr, indicating no profit during that time.<BR><BR>The latest reporting period for the balance sheet is March 2026. Shareholder's funds were recorded at 12.79 Cr, while total assets amounted to 24.81 Cr.

Which are the latest news on Link Pharma Chem?

Are Link Pharma Chem Ltd latest results good or bad?

Link Pharma Chem Ltd's latest results show a 33.08% revenue growth to ₹8.77 crores, indicating short-term recovery; however, net profit declined by 20% and operating margins fell, highlighting ongoing profitability challenges and weak long-term fundamentals. Investors should exercise caution due to these structural issues.

Link Pharma Chem Ltd's latest results present a mixed picture. On one hand, the company achieved a significant sequential revenue growth of 33.08%, reaching ₹8.77 crores in Q1 FY27, which is a positive indicator of short-term recovery. However, this growth comes with notable concerns.<BR><BR>Despite the revenue increase, the net profit for the quarter was ₹0.32 crores, which is a decline of 20% compared to the same quarter last year. Furthermore, the operating margin has decreased to 5.13% from 8.19% year-on-year, indicating that the company is struggling with cost management and profitability. The profit margins, both operating and PAT, have deteriorated, reflecting ongoing challenges in the competitive commodity chemicals sector.<BR><BR>Additionally, the long-term fundamentals of the company appear weak, with a five-year sales CAGR of -4.66% and EBIT CAGR of -26.52%. This suggests that the company has faced sustained contraction in revenue and operating profits over the years.<BR><BR>Overall, while there are signs of a short-term recovery in revenue, the underlying issues with profitability and long-term growth prospects suggest that the results are more concerning than encouraging. Investors should be cautious given the structural challenges the company faces.

Should I buy, sell or hold Link Pharma Chem Ltd?

When is the next results date for Link Pharma Chem Ltd?

Link Pharma Chem Ltd will announce its results on 05 August 2026.

Link Pharma Chem Ltd is scheduled to declare its results on 05 August 2026.

How has been the historical performance of Link Pharma Chem?

Link Pharma Chem has experienced a significant decline in net sales and profitability, with losses reported in the most recent fiscal year. Net sales dropped from 53.56 Cr in March 2022 to 25.43 Cr in March 2025, and the company reported a profit after tax loss of -1.03 Cr in March 2025.

Answer:<BR>The historical performance of Link Pharma Chem shows a declining trend in net sales and profitability over the past few years, culminating in losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Link Pharma Chem's net sales have decreased from 53.56 Cr in March 2022 to 25.43 Cr in March 2025, reflecting a significant decline. The total operating income followed a similar trend, dropping from 53.56 Cr in March 2022 to 25.43 Cr in March 2025. The company's total expenditure also decreased, but not as sharply, leading to operating profits that turned negative in March 2024 and remained low at 0.31 Cr in March 2025. Profit before tax has been negative since March 2024, with a loss of 1.40 Cr reported in March 2025. Consequently, the profit after tax also showed losses, amounting to -1.03 Cr in March 2025. The company's total assets decreased from 32.46 Cr in March 2023 to 23.06 Cr in March 2025, while total liabilities also fell from 25.95 Cr to 23.06 Cr in the same period. Cash flow from operating activities was positive at 2.00 Cr in March 2025, but the overall cash position remained stagnant, with no cash inflow or outflow reported. Overall, Link Pharma Chem has faced significant challenges, leading to declining revenues and profitability over the years.

Is Link Pharma Chem overvalued or undervalued?

As of May 28, 2025, Link Pharma Chem is considered risky and overvalued with a negative PE ratio of -15.17 and a year-to-date return of -12.29%, significantly underperforming compared to its peers like Godrej Industries and the Sensex.

As of 28 May 2025, the valuation grade for Link Pharma Chem has moved from very attractive to risky. The company is currently assessed as overvalued, given its negative PE ratio of -15.17, an EV to EBITDA of 22.01, and a ROE of -7.51%. These ratios indicate significant financial distress and a lack of profitability, which is concerning for potential investors.<BR><BR>In comparison to its peers, Link Pharma Chem's valuation metrics starkly contrast with those of Godrej Industries, which has a PE ratio of 46.63 and an EV to EBITDA of 34.36, indicating a more favorable market position. Additionally, Solar Industries is deemed very expensive with a PE ratio of 123.77, highlighting the disparity in valuation within the sector. Despite a recent uptick in stock price, Link Pharma Chem's year-to-date return of -12.29% significantly underperforms the Sensex's 5.66%, reinforcing the notion of its overvaluation.

What is the technical trend for Link Pharma Chem?

As of June 5, 2025, Link Pharma Chem's trend has shifted to bearish, supported by bearish indicators from moving averages and Bollinger Bands, despite some mixed signals from the MACD and KST.

As of 5 June 2025, the technical trend for Link Pharma Chem has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD indicates a bearish trend. Both the weekly and monthly Bollinger Bands confirm a bearish outlook. Daily moving averages are also bearish, reinforcing the negative sentiment. The KST shows a mildly bullish signal on the weekly chart, but is bearish on the monthly, indicating mixed signals. Overall, the lack of clear trends in Dow Theory further supports a bearish perspective.

Who are the top shareholders of the Link Pharma Chem?

The top shareholders of Link Pharma Chem include Rishikesh Satishbhai Thakur with 18.95%, followed by Gurudev Marketing Pvt. Ltd. at 5.76%, and individual investors holding 37.17%. There are no pledged promoter holdings, minimal mutual fund involvement, and no foreign institutional investors.

The top shareholders of Link Pharma Chem include the promoters, with Rishikesh Satishbhai Thakur holding the largest share at 18.95%. The company has no pledged promoter holdings. In terms of public shareholders, Gurudev Marketing Pvt. Ltd. is the highest public shareholder with a stake of 5.76%. Additionally, individual investors collectively hold 37.17% of the shares. Mutual funds have a minimal presence, with only one scheme holding 0.02%, and there are currently no foreign institutional investors (FIIs) involved.

Has Link Pharma Chem declared dividend?

No Dividend History Available